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Abstract
Background: Tuberculosis (TB) in children is frequently paucibacillary and non-severe forms of pulmonary TB are
common. Evidence for tuberculosis treatment in children is largely extrapolated from adult studies. Trials in adults
with smear-negative tuberculosis suggest that treatment can be effectively shortened from 6 to 4 months. New
paediatric, fixed-dose combination anti-tuberculosis treatments have recently been introduced in many countries,
making the implementation of World Health Organisation (WHO)-revised dosing recommendations feasible. The
safety and efficacy of these higher drug doses has not been systematically assessed in large studies in children, and
the pharmacokinetics across children representing the range of weights and ages should be confirmed.
Methods/design: SHINE is a multicentre, open-label, parallel-group, non-inferiority, randomised controlled, two-arm
trial comparing a 4-month vs the standard 6-month regimen using revised WHO paediatric anti-tuberculosis drug
doses. We aim to recruit 1200 African and Indian children aged below 16 years with non-severe TB, with or without
HIV infection. The primary efficacy and safety endpoints are TB disease-free survival 72 weeks post randomisation
and grade 3 or 4 adverse events. Nested pharmacokinetic studies will evaluate anti-tuberculosis drug
concentrations, providing model-based predictions for optimal dosing, and measure antiretroviral exposures in
order to describe the drug-drug interactions in a subset of HIV-infected children. Socioeconomic analyses will
evaluate the cost-effectiveness of the intervention and social science studies will further explore the acceptability
and palatability of these new paediatric drug formulations.
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Discussion: Although recent trials of TB treatment-shortening in adults with sputum-positivity have not been
successful, the question has never been addressed in children, who have mainly paucibacillary, non-severe smear-
negative disease. SHINE should inform whether treatment-shortening of drug-susceptible TB in children, regardless
of HIV status, is efficacious and safe. The trial will also fill existing gaps in knowledge on dosing and acceptability of
new anti-tuberculosis formulations and commonly used HIV drugs in settings with a high burden of TB. A positive
result from this trial could simplify and shorten treatment, improve adherence and be cost-saving for many children
with TB.
Recruitment to the SHINE trial begun in July 2016; results are expected in 2020.
Trial registration: International Standard Randomised Controlled Trials Number: ISRCTN63579542, 14 October 2014.
Pan African Clinical Trials Registry Number: PACTR201505001141379, 14 May 2015.
Clinical Trial Registry-India, registration number: CTRI/2017/07/009119, 27 July 2017.
Keywords: Tuberculosis, Efficacy, HIV, Shorter course, Child,
Background
Disease setting and context in the study
Of the estimated 10.4 million new tuberculosis (TB)
cases globally per annum, approximately one million
occur in children in Africa and South East Asia [1]. In
Africa, where the TB and HIV epidemics are closely
linked, children contribute approximately 30% of inci-
dent TB cases [2–4]. Furthermore, in countries with
high HIV prevalence, the peak age-prevalence of TB has
shifted towards younger adults. These adults are often
parents of young children, increasing the exposure of
children to TB. Among both HIV-infected children and
adults, TB remains a leading cause of death and is the
most common opportunistic infection, despite improved
access to antiretroviral therapy (ART) [5–7].
Historically, studies of anti-tuberculosis treatment in chil-
dren have lagged substantially behind adult studies and data
regarding TB treatment extrapolated from adults. Children
have also been seen to pose little risk of onward transmis-
sion. In combination with the challenges in confirming a
TB diagnosis in children and the resource constraints, the
focus has been on adult trials. The approaches used to treat
childhood TB have relied on extrapolation to children of
the evidence from clinical trials in adults who have a differ-
ent spectrum of TB disease and lower bacillary burden [8].
The spectrum of TB disease in children
The TB disease spectrum observed in children is differ-
ent compared to adults [9, 10]. Whereas a higher pro-
portion of young children (below 3 years) have
disseminated forms of TB, including miliary TB and TB
meningitis, [9] primary childhood TB is typically more
benign than adult TB. Three-quarters of children have
intrathoracic TB, mainly with non-severe forms of intra-
thoracic lymph node TB [10–12]. Adult forms with
pleural effusions and cavitation commonly emerge dur-
ing adolescence [13].
TB diagnosis and measuring response to treatment in
children
Microbiological confirmation of TB in younger children,
who have the highest risk of TB disease, is challenging as
they cannot spontaneously produce sputum. In addition,
most children with pulmonary (intrathoracic) TB typically
have paucibacillary disease. Of the 75% of children with in-
trathoracic disease, more than 85% have negative-smear mi-
croscopy on respiratory samples [11, 12]. Confirmation by
culture (the diagnostic ‘gold standard’) is typically made only
in approximately 30% of children [11, 14]. Of note, positive
culture can also occasionally be obtained in children with
normal chest radiographs and a positive tuberculin skin test
or history of Mycobacterium tuberculosis exposure [15–17].
Therefore, the diagnosis of intrathoracic tuberculosis in chil-
dren frequently relies on non-specific clinical symptoms and
signs, supported by evidence of TB contact and/or TB infec-
tion and changes on chest radiography [18].
Data on objective measures of TB treatment response
in children are limited. Response to anti-tuberculosis
treatment can be evaluated by resolution of clinical
symptoms, radiological features and smear and culture
conversion in bacteriologically confirmed cases. Radio-
logical resolution has limitations as some features may
temporarily worsen and residual changes may persist at
the end of treatment [19–22]. Repeat microbiological
sampling during therapy may also not be feasible in the
majority of children who stop coughing early in treat-
ment. Although well-defined clinical case definitions for
research are useful for TB diagnosis and evaluation of
treatment response in paediatric studies, [8, 23] there
are no published data on the gold standard of TB treat-
ment response, i.e. long-term relapse-free survival.
Drug doses and fixed-dose formulations of anti-
tuberculosis drugs in children
The doses of first-line anti-tuberculosis drugs recom-
mended for children have been based on the same dose
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per kilogram of body weight that is recommended for
adults [8]. In 2010, the WHO revised the doses of the
first-line TB drugs in children, increasing daily doses of
isoniazid (H) from 5 to 10 mg/kg, rifampicin (R) from
10 to 15 mg/kg, pyrazinamide (Z) from 25 to 35 mg/kg
and recommending ethambutol (E) at a dose of 20 mg/kg/
day [24]. The change was triggered by a review of the aca-
demic literature including pharmacokinetic (PK) studies
showing that doses extrapolated from adults do not
achieve comparable drug exposures in children [25–29].
With the revised doses it was thought to be possible to at-
tain similar rifampicin, isoniazid and pyrazinamide con-
centrations to those in adults on standard doses [30–32].
WHO-recommended increased drug doses were diffi-
cult to implement in children using the original fixed-
dose combination (FDC) RHZ 60/30/150 mg which, in
particular, delivered low isoniazid doses [33]. New co-
formulated RHZ 75/50/150 mg FDC tablets were
launched in 2015 with rapid and wide uptake globally
[34]. The new FDC, which we use in the SHINE trial, fa-
cilitates achieving the recommended doses [35].
Anti-TB and antiretroviral treatment interactions in HIV
co-infected children
Rifampicin interacts with many antiretroviral drugs
necessitating ART adjustment for children. For children
≥ 3 years, efavirenz-based ART is preferred during co-
administration of anti-tuberculosis drugs as efavirenz
has minimal drug interactions with rifampicin. For chil-
dren < 3 years on lopinavir/ritonavir-based ART, two op-
tions are available: first, super boosting with additional
ritonavir to overcome the rifampicin-inducing effect of
liver enzymes, and second, changing to three nucleoside
reverse transcriptase inhibitors (NRTIs) [36]. However,
neither option is optimal. Super boosting with separate
liquid ritonavir is frequently not feasible due to its un-
availability, complexity of administration, short shelf-life
and poor tolerability [37], and triple NRTI ART is less
efficacious in viral suppression [38]. Alternative solu-
tions for child-friendly dosing are urgently required for
young children [36, 39].
TB treatment-shortening trials in adults
Early trials in HIV-negative adults with smear-negative
TB in Hong Kong and Singapore showed that, in
principle, reductions of treatment duration from 6 to
4 months have resulted in relapse rates of only 4% [40–
42]. WHO guidelines subsequently recommended 4-
month treatment duration for smear-negative TB in
1993, although this decision was soon reversed [43]. Re-
cent trials of treatment-shortening in adults with smear
positive TB have demonstrated poorer outcomes associ-
ated with shorter regimens [44–46]. However, there is
no trial evidence about optimum regimen duration for
children.
Rationale for the trial
The implementation of standard regimens for both
adults and children is attractive for TB programmes.
The needs of children with TB, who potentially benefit
from shorter treatment and who form a considerable
proportion of the global disease burden, should be ad-
dressed. The costs to children and their families, burden
to health services and added toxicity associated with po-
tentially overly long treatment regimens should be also
considered. In addition, risks of suboptimal HIV control
from drug-drug interactions, the increased pill-burden
and its effect on adherence are significant issues for
HIV-co-infected children [47] which could be amelio-
rated by shortening TB treatment.
Treatment outcomes appear considerably better in
children than adults with multi-drug resistant (MDR)
TB [48], likely because most children have paucibacillary
disease. It therefore follows that TB outcomes for
shorter first-line regimens could be as good as the longer
regimens currently used in adults and children [49, 50].
In addition, there are similarities between minimal TB
disease in children and smear-negative, paucibacillary
TB in adults, in whom trials of shorter regimens have
suggested success. This makes the implementation of tri-
als of shorter treatment of standard first-line regimens
conducted in children all the more important, and in
different countries where the metabolism of anti-
tuberculosis drugs may differ (India/Africa). Finally, re-
vised WHO dosing guidelines for TB drugs aim to
achieve substantially higher TB drug exposures in
children which should be more efficacious, providing add-
itional rationale to perform this treatment-shortening trial
at the time that these dosing guidelines are being imple-
mented globally.
Aims
The primary aim of the trial is to determine whether the
standard 6-month regimen (8 weeks’ HRZE followed by
16 weeks’ HR) can be reduced with similar efficacy, to
4 months’ (8 weeks’ HRZE followed by 8 weeks’ HR), in
African and Indian children with non-severe TB and re-
gardless of HIV status, using revised WHO dosing
guidelines and recently introduced new paediatric fixed-
dose combination tablets.
The other objectives are:
1. To determine whether the higher WHO-
recommended doses of daily first-line anti-TB
drugs, given as fixed-dose combination dispersible
tablets, and prescribed according to weight bands,
give appropriate drug exposures when compared
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with historical paediatric and adult pharmacokinetic
(PK) data
2. To determine, among HIV-infected children, whether
currently recommended adjusted strategies and doses
of antiretroviral drugs can appropriately overcome
the effect of rifampicin at the new higher doses
Methods
Trial design
SHINE is an open-label, phase II/III, non-inferiority trial.
Participants are randomised in a 1:1 ratio to the experi-
mental 4-month or standard 6-month treatment arm.
Both arms have an 8-week intensive phase with rifampi-
cin, isoniazid, pyrazinamide and ethambutol followed by
a continuation phase with rifampicin and isoniazid given
for 8 weeks in the shorter arm vs 16 weeks in the stand-
ard arm (Fig. 1).
Setting and population
The study recruits children aged < 16 years diagnosed
with minimal non-severe TB from diverse populations in
three sites in Africa (Cape Town, South Africa; Kampala,
Uganda; Lusaka Zambia) and two sites in India (Pune
and Chennai). The trial sites were selected based on the
expertise of treating children with TB, sufficient clinical
trial experience and the potential for recruiting the re-
quired number of suitable participants within the agreed
recruitment period.
The patient inclusion and exclusion criteria are de-
tailed in Table 1.
Definition of minimal (non-severe) TB
Minimal TB in this protocol refers to a form of non-
severe, symptomatic, smear-negative TB including
extrathoracic lymph node TB, intrathoracic uncompli-
cated lymph node TB and other non-severe forms of pul-
monary TB as per an established classification system [51].
Endpoints
Primary outcome
The main trial outcome for efficacy is categorised as
follows:
1. Favourable outcome; TB-free survival at week 72
post randomisation
2. Unfavourable outcomes; a composite of death,
reinfection or recurrence
3. Not assessable; will include unknown outcomes at
trial completion such as losses to follow-up after
completing treatment and clinically well when last
seen.
The safety endpoint will be grade 3 and 4 adverse
events.
Secondary outcomes
1. Mortality
2. Adverse drug reactions within 30 days of
completing treatment
3. Relapse/re-infection-free survival including only
cases adjudicated to be TB by an independent
Endpoint Review Committee
4. HIV viral suppression at weeks 24 and 48 in
HIV-infected children
5. Adherence and acceptability
6. Bacterial infections requiring hospitalisation
Fig. 1 Trial schema
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Screening and enrolment procedures
The standard screening procedures include: a chest radio-
graph (CXR) and at least two consecutive respiratory sam-
ples including gastric aspirate, expectorated or induced
sputum for smear microscopy, Xpert MTB/RIF© (Xpert;
Cepheid, Sunnydale, CA, USA), culture and drug-
susceptibility testing (DST). In children with extrathoracic
cervical lymphadenopathy, lymph node needle aspiration
will be undertaken. A Mantoux test or IGRA (interferon-
gamma release assay) will be done as available.
At enrolment, a clinical history and physical examin-
ation is performed including measurements of weight,
height, mid-upper arm circumference, paediatric WHO
staging for HIV and signs/symptoms suggestive of TB.
Randomisation and allocation
Randomisation is undertaken at each site using a web-based
system controlled through an authorised username and
password. The method of minimisation with a random
element is employed. To reduce potential predictability of
the randomisation in this open-label study, the minimisation
factors are not disclosed to the investigators.
Trial interventions
Children randomised to the 4-month arm receive rifam-
picin, isoniazid and pyrazinamide (plus ethambutol
where given as part of standard care treatment) for an 8-
week intensive phase followed by isoniazid and rifampicin
for a continuation phase of a further 8 weeks. In the 6-
month arm, children receive the same intensive phase as the
other group followed by a continuation phase of 16 weeks.
TB treatment products, dosing schedule and treatment
supervision
Anti-TB drugs are administered according the WHO
dosing recommendations using new FDCs and new
weight bands for children weighing < 25 kg (Table 2).
Children weighing ≥ 25 kg are treated according to adult
guidelines (Table 3).
Treatment is implemented in accordance with each
site’s local practice. Typically this involves daily adminis-
tration by the child’s carer(s) and documenting ingestion
on TB treatment cards provided by the trial.
Adherence to trial medication is assessed by pill
counts, specific adherence questions at each 4-weekly
visit, as well as the number of doses recorded on the TB
treatment card.
Protocol treatment discontinuation
Protocol treatment discontinuation is considered under
any of the following circumstances:
1. Unacceptable toxicity or adverse event
2. Disease progression necessitating change of regimen
(e.g. with drug-resistant TB or complication of disease)
3. Withdrawal of consent for treatment or participa-
tion by the participant’s carer/guardian
4. Participant’s DST-identifying drug resistance, in-
cluding isoniazid mono-resistance
The children whose protocol treatment is discontinued
remain in the trial for the purpose of follow-up and data
analysis (unless the carer withdraws consent). Data are
kept and included for participants who stop follow-up
early, up to the point of exit.
Non-trial treatment
HIV-infected children enrolled in the trial are provided
with ART in accordance with local country programmes
including alternative ART drugs regimens indicated for
concomitant use with rifampicin during the duration of
the TB treatment. All HIV-infected children with TB re-
ceive co-trimoxazole prophylaxis as per local guidelines.
Trial assessments and follow-up
All participants are seen at screening, enrolment/randomisa-
tion and then at weeks 2, 4, 8, 12, 16, 20, 24, 28, 36, 48, 60
and finally at week 72, when they will exit the trial (Fig. 2).
A symptom checklist is performed at each visit to de-
tect inter-current illnesses, new TB exposure including
DR-TB, TB treatment failure/recurrence or relapse or
adverse events to TB drugs (and ART if applicable).
Table 1 Patient inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
1. Age 0–16 years
2. Weight ≥ 3 kg
3. Clinician has decided to treat with
standard first-line regimen (intensive
phase of 4 drugs or 3 drugs as per
local practice)
4. Symptomatic but non-severe TB
including:
a. extrathoracic lymph node TB;
intrathoracic uncomplicated (hilar)
lymph node TB
b. minimal or no parenchymal
abnormality on CXR
c. smear-negative on gastric
aspirate/other respiratory sample
Note: GeneXpert may be positive or
negative and a negative GeneXpert can
be used as a substitute for a negative
smear; culture of respiratory sample may
be positive or negative; lymph node
aspirate may be smear/culture/
GeneXpert positive or negative)
5. Not treated for previous TB unless
successfully treated > 2 years since
last completed treatment
6. Known (or pending confirmation
of)HIV status; HIV-infected or HIV-
uninfected
7. Willing and likely to adhere to
72 weeks’ follow-up
8. Informed written consent from the
parent/legal caregiver(s) and assent
in children, as per local Ethics
Committee guidance
9. Home address accessible for visiting
and intending to remain within the
recruitment area for follow-up.
1. Smear-positive respiratory sample
2. Premature (< 37 weeks) and aged
under 3 months
3. Miliary tuberculosis (TB), spinal TB, TB
meningitis, osteoarticular TB,
abdominal TB, congenital TB
4. Pre-existing non-tuberculous
disease likely to prejudice the
response to, or assessment of, treat-
ment, e.g. liver or kidney
disease, peripheral neuropathy,
cavitation
5. Any known contraindication to
taking anti-TB drugs
6. Known contact with drug-resistant
adult source case (including mono-
resistant TB)
7. Known drug resistance in the child
8. Severely ill
9. Pregnancy
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Respiratory samples for TB assessment and blood sam-
ples for biochemistry and haematology, as well as
lymphocyte subsets and HIV1 viral load in HIV-infected
children, are obtained as summarised in Fig. 2. Relevant
samples are stored for pharmacogenomics, biomarkers
and hair PK substudies at pre-specified time points (Fig.
2). A quality of life questionnaire, adapted for younger
children from a standardised EQ-5D questionnaire [52],
is administered at weeks 0, 16, 24, 48 and 72.
Participants are expected to attend all scheduled visits
unless agreed in advance with the study team. Additional
study visits are arranged when a participant misses a
clinic visit or whenever clinical care is required.
Procedures for assessment of TB diagnosis and treatment
response
TB diagnosis and treatment response will be adjudicated
by an Endpoint Review Committee (ERC) with independ-
ent chair and membership. The ERC will review the end-
points (treatment failure or recurrence) and cause of
death against standard criteria [23], blinded to treatment
allocation, based on all available clinical, microbiological
and molecular data obtained from the follow-up assess-
ments and procedures. TB disease severity at diagnosis
will be ascertained using Wiseman criteria [51].
CXRs are repeated at week 24, for suspected treatment
failure or TB recurrence, and if clinically indicated. All
CXRs will be prospectively read by the study site clinician
to check eligibility for enrolment and retrospectively
reviewed centrally by independent experts blind to treat-
ment allocation using a standardised approach. Where
available, Mantoux/IGRA is repeated at week 12 or 16 if
the initial test was negative or missed at screening.
At each visit a clinical examination for TB signs and
symptoms and new TB exposure is conducted to identify
children with possible treatment failure or recurrence.
Repeat specimens for smear microscopy and culture for
M. tuberculosis are collected if clinically indicated. For
children with culture-positive respiratory specimens, re-
peat TB microscopy and culture are attempted every
2 months until culture conversion. Lymph node needle as-
piration is not routinely repeated during follow-up.
Procedures for assessing safety
Symptoms checklists and laboratory investigations are
performed as part of safety monitoring at predetermined
intervals (Fig. 2). In the case of adverse events, add-
itional tests are done as clinically indicated.
To monitor for the potential ocular toxicity with etham-
butol use, colour-vision testing is done at screening and at
week 8 for children aged 3 years and older, with repeat
testing at 16 weeks only in those patients with abnormal
results. Children with obvious symptoms at any time
within the intensive phase of treatment are referred to an
ophthalmologist for further testing as appropriate. In the
event of confirmed ocular toxicity, ethambutol is stopped.
For girls of reproductive age, or who have started men-
ses, a pregnancy test is performed at screening. Any girl
found to be pregnant is not eligible for the trial. Girls who
become pregnant during the trial will be closely moni-
tored and followed for treatment and pregnancy outcome.
Substudies
Pharmacokinetic (PK) studies
The trial includes two PK substudies. The first includes
65 children and describes the PK parameters of rifampi-
cin, isoniazid and pyrazinamide when administered in
the new FDC according to WHO weight-band doses in
Table 2 Number of tablets to be taken once daily based on WHO guidelinesa
Weight
bands
Intensive phase Continuation phase
50H, 75R, 150Z 100Eb 50H, 75R
3.0–3.9 kg 0.75 0.75 0.75
4.0–7.9 kg 1 1 1
8.0–11.9 kg 2 2 2
12.0–15.9 kg 3 3 3
16.0–24.9 kg 4 4 4
≥ 25.0 kg Adult formulation and doses Adult formulation and doses Adult formulation and doses
R rifampicin, H isoniazid, Z pyrazinamide, E ethambutol
aH: 10 mg/kg (range 7–15 mg/kg) to a maximum dose 300 mg/day; R: 15 mg/kg (range 10–20 mg/kg) to a maximum dose 600 mg/day; Z: 35 mg/kg (30–40 mg/
kg); E: 20 mg/kg (15-25 mg/kg)
b100E: additional, separate, single-dose E 100-mg tablets, where this is given as part of local practice, are provided for the intensive phase
Table 3 Number of tablets to be taken by children weighing ≥
25 kg based on WHO adult tuberculosis (TB) guidelinesa
Weight
bands
Intensive phase Continuation phase
75H, 150R, 400Z, 275Eb 75H, 150R
25–36.9 kg 2 2
37–54.9 kg 3 3
55–70.0 kg 4 4
aH: 5 mg/kg (range 4–6 mg/kg) to a maximum dose 300 mg/day; R: 10 mg/kg
(range 8–12 mg/kg) to a maximum dose 600 mg/day; Z: 25 mg/kg (20–30 mg/
kg); E: range 15–20 mg/kg; bEither HRZE or HR fixed-dose combinations with
additional Z
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children weighing < 25 kg, or the adult formulation for
children 25 to < 37 kg [18]. Ethambutol will be measured
in the subset of children treated with this fourth drug.
The second substudy evaluates PK interactions between
anti-TB and antiretroviral drugs (efavirenz, lopinavir, rito-
navir, nevirapine, abacavir and zidovudine) in up to 60
HIV-infected children on ART. Children have cross-over
intensive PK undertaken during the continuation phase
and 4 weeks after stopping anti-TB treatment.
For both studies, seven blood samples (0.8 ml each)
are collected before drug intake and then at 1, 2, 4, 6, 8
and 12 h after drug intake for intensive PK.
Hair PK sub-study
Novel assays to measure concentrations of two TB drugs,
isoniazid and pyrazinamide, in small hair samples have
been developed and validated. These assays have the poten-
tial to monitor adequate drug adherence and exposure and
need further investigation. In the SHINE study, small hair
samples are being collected in around 600 consenting par-
ticipants to evaluate hair concentrations of isoniazid and
pyrazinamide as surrogates of adherence and predictors of
TB treatment outcomes (e.g. treatment success, recurrence
and death) among HIV-infected and uninfected children.
Health economics
Economic evaluation of the alternative interventions will
be undertaken. Resource use data are collected in the trial
on health care visits, hospitalisations, TB and HIV medica-
tions, concomitant medications, and diagnostic tests. Esti-
mates of the total costs of the two treatment strategies
from a health sector perspective will be made using na-
tionally representative unit costs combined with resource
use data. Health outcomes will be estimated in terms of
life years gained (LYGs), quality-adjusted life years
(QALYs) and disability-adjusted life years (DALYs). The
adapted quality of life questionnaire [52] will be combined
with existing tariffs to estimate QALYs. Existing DALY
weights for TB and TB-free survival will be used.
The nature of the economic analyses will largely de-
pend upon the trial results. If the shortened regimen
arm is non-inferior, and is not associated with any add-
itional costs, this will indicate its cost-effectiveness. The
cost savings from adopting this strategy at the national
level will then be estimated based upon national esti-
mates of childhood TB incidence. If the longer regimen
arm is shown to be more effective, a cost-effectiveness
analysis will be undertaken to investigate whether this
represents ‘value for money’ to each of the health care
systems in terms of the cost per QALY/DALY/LYG, and
estimates of the opportunity costs of resources required
to fund the intervention.
Social science
The substudy evaluates palatability and acceptability of
the new FDC using acceptability questionnaires and
semi-structured interviews in health facilities and at the
homes of a subset of the South African trial population.
Challenges with administration of the anti-TB drugs and
differences between clinical advice and practice, as well
as changes in administration and acceptability over the
period of treatment, will be described.
Fig. 2 SHINE trial assessment and follow-up schedules
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Statistical considerations
Sample size and power
It is expected that TB recurrence (relapse or re-
infection) and mortality rates will differ by HIV status
and co-administration of ART. Based on estimates from
the ARROW trial (Uganda and Zimbabwe) [53] and rou-
tine data from paediatric HIV clinics in South Africa, we
estimate mortality in children HIV-negative, HIV-
infected children on and not on ART to be 2%, 5% and
7%, respectively, over 18 months. Corresponding % esti-
mates for TB recurrence are 3%, 4% and 6%, respect-
ively, in these three groups. We assume that the
proportion of HIV-infected children will be approxi-
mately 35% maximum (averaged across sites), of whom
the majority will be on ART at the start of TB therapy.
Using these estimates, the overall rate of TB recurrence
or death was estimated at approximately 8%.
Non-inferiority margin
In discussion with study investigators, 6% was consid-
ered a reasonable margin of non-inferiority for the ex-
perimental arm for the endpoint of relapse or re-
infection-free survival. This has been used in previous
treatment-shortening phase III trials in adult smear-
positive TB [45, 46].
Based on these assumptions, the total number of evalu-
able children required to demonstrate non-inferiority be-
tween the short-regimen arm and the control arm (90%
power, one-sided 97.5% confidence intervals (CIs)), would
be 860 across two arms. Based on experience from other
phase III TB trials, 10% loss-to-follow-up was considered
reasonable, resulting in a total of 956 children.
It is expected that a proportion of enrolled children
treated for TB will not actually have TB, thus reducing
the recurrence rate and increasing the chance of demon-
strating non-inferiority. For this reason, although the
primary analysis will include all randomised children
(with assessable outcomes), a key secondary analysis will
exclude children (assumed 20%) considered by the inde-
pendent Blinded-endpoint Review Committee not to
have TB at enrolment.
Due to the importance of this analysis the trial will be
powered to demonstrate non-inferiority also in this sub-
population, resulting in a total of 1200 children to be
enrolled.
Analysis plan
There will be two main analysis populations: the modi-
fied intention-to-treat (MITT) and per-protocol (PP)
analysis populations. While both of these will be consid-
ered primary in order to declare non-inferiority, consist-
ent results should be obtained from key subgroup
analyses (confirmed TB cases, both MITT and PP) and
sensitivity analyses, although not all of these will
necessarily need to satisfy the strict definition of non-
inferiority.
The MITT analysis will include all randomised partici-
pants excluding those withdrawn from treatment be-
cause of a protocol violation at enrolment (late
exclusions from the study, based on data collected prior
to randomisation). The PP analysis will be restricted to
participants who have received an adequate amount of
study treatment. Any further exclusions in both MITT
and PP populations will be detailed in the statistical ana-
lysis plan.
Definition of adequate treatment
The definition of adequate treatment sets limits both for
the amount of treatment missed in each treatment phase
and the amount of treatment missed overall. This defin-
ition of adequate treatment has been used in adult TB
trials and is based on receiving at least 80% of the pre-
scribed doses within a pre-specified time frame [45].
Primary efficacy analysis
The primary efficacy analysis will be the difference in pro-
portions of the unfavourable outcomes (proportion with
unfavourable outcome on the 4-month regimen arm less
the proportion with unfavourable outcome on the 6-
month regimen) adjusted for the minimisation factors.
Non-inferiority will be assessed using the upper bound
of the one-sided 97.5% CI for this difference. If the
upper bound of this CI is less than 6% (the margin of
non-inferiority) the 4-month regimen will be considered
non-inferior to the 6-month regimen.
PK substudies analysis plan
Non-linear mixed effects (NLME) models will be used to
describe the population PK of the TB and ART drugs
taking account of age, weight, race (African/Asian) and
actual dose. In addition to describing the PK for each
drug, these models would account for any non-linearity
in the PK related to dose.
Differences in the Area Under the Curve (AUC) by
age, HIV status, and between Asian vs African would be
determined using model-based individual post-hoc
Bayesian estimates. The geometric mean ratios of the
post-hoc estimates of the AUCs for the TB drugs in the
FDC compared to single drugs in regulatory approved
products will be computed and evaluated against bio-
equivalence criteria.
Safety reporting
Adverse events and adverse reactions
The definitions of adverse events (AE) and adverse reac-
tions (AR) outlined in the EU Directive 2001/20/EC Art-
icle 2 based on the principles of ICH GCP apply to this
trial protocol (Table 4) [54].
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The investigational medicinal products in this trial will
be rifampicin, isoniazid, pyrazinamide and ethambutol.
ARs include any untoward or unintended response to
any of these drugs.
All AEs meeting the standard definitions above are re-
ported, regardless of their relationship to TB. The ser-
iousness of the events is assessed using the ICH-GCP
definitions, and severity is determined in accordance
with the 2014 Division of AIDS toxicity grading scale
[55]. The causality and expectedness of all serious events
or reactions in relation to the trial drugs is categorised
as unrelated, unlikely, possibly, probably and definitely
related, and for the latter three categories as expected
and unexpected based on the Summary of Product
Characteristics.
All SAEs, grade 3/4 adverse reactions and notable
events (ocular toxicities, pregnancies and bacterial
infections requiring hospitalisation) are notified to the
Medical Research Council Clinical Trials Unit (MRC
CTU) within one working day of the investigator be-
coming aware of the event. Other reportable events are
reported within seven working days. The investigators at
each site are also responsible for the onward reporting
of adverse events to their ethics and regulatory bodies,
as per their local reporting requirements. MRC CTU is
responsible for annual onward reporting of a line listing
of events to the trial sponsor, University College London
(UCL). Investigators are responsible for reporting all
SAEs, notable events and other adverse events meeting
their reporting requirements that occur from the time of
randomisation until 30 days after the last protocol treat-
ment administration.
Quality assurance, data management and monitoring
UCL is responsible for trial oversight and ensuring that
arrangements are in place for adequate management,
monitoring, analysis and reporting of the trial.
Quality assurance and quality control are based on a
formal risk assessment which leads to the development
of the trial quality management plan implemented by
the sponsor. On-site monitoring and data validation and
assessment of adherence to International Conference on
Harmonisation-Good Clinical Practice (ICH-GCP) prin-
ciples is regularly conducted by independent local moni-
tors at each site and periodically directly by MRC CTU
on behalf of the sponsor. Each site is responsible for its
own data entry and local trial management.
Trial governance
The trial is overseen by a number of committees each
with distinct functions and membership. The Trial Steer-
ing Committee (TSC) consists of the chief investigator,
site principal investigators and independent members.
The TSC provides overall supervision for the trial and
advice through its independent chair. The ultimate deci-
sion for the continuation of the trial lies with the TSC.
The Independent Data Monitoring Committee
(IDMC) reviews confidential, accumulating data for the
trial produced by the trial statisticians. The functions
and frequency of its meeting are dictated by the DMC
charter. The IDMC can recommend premature closure
or reporting of the trial.
The Endpoint Review Committee (ERC), blinded to
the trial arm, will determine the primary endpoint classi-
fication for all participants as favourable, unfavourable
or unassessable. In addition, the ERC will examine evi-
dence and adjudicate causes of death based on all avail-
able sources of data and determine the TB diagnosis at
enrolment across sites for the key secondary analysis of
those with definitive TB [23].
Table 4 Safety reporting definitions
Term Definition
Adverse event (AE)a Any untoward medical occurrence in
a patient or clinical trial subject to
whom a medicinal product has been
administered including occurrences
that are not necessarily caused by or
related to that product
Adverse reaction (AR) Any untoward and unintended
response to an investigational
medicinal product related to any
dose administered
Unexpected adverse
reaction (UAR)
An adverse reaction, the nature or
severity of which is not consistent
with the information about the
medicinal product in question set
out in the Summary of Product
Characteristics (SPC) or Investigator
Brochure (IB) for that product
Serious adverse event (SAE) or
serious adverse reaction (SAR) or
suspected unexpected serious
adverse reaction (SUSAR)
Respectively, any adverse event,
adverse reaction or unexpected
adverse reaction that:
Results in death
Is life-threatening
Requires hospitalisation or
prolongation of existing
hospitalisation
Results in persistent or significant
disability or incapacity
Consists of a congenital anomaly or
birth defect
Is another important medical
condition
aAEs will include; an exacerbation of a pre-existing illness, an increase in
frequency or intensity of a pre-existing episodic event or condition, a condition
(even though it may have been present prior to the start of the trial) detected
after trial drug administration or continuous persistent disease (or a symptom
present at baseline) that worsens following administration of the
study treatment
Conditions exempted from AEs will include; medical or surgical procedures
(the condition that leads to the procedure is the adverse event), pre-existing
disease or a condition present before treatment that does not worsen,
hospitalisations where no untoward or unintended response has occurred
(e.g. elective cosmetic surgery, social admissions) or overdose of medication
without signs or symptoms
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Discussion
SHINE is the first large-scale paediatric trial that will
test whether 4-month therapy is as effective as the
standard 6-month course in children with non-severe
TB. Recently, three large multicentre trials to determine
whether fluoroquinolone-containing regimens can
shorten treatment from 6 to 4 months did not demon-
strate non-inferiority of the 4-month regimens in adults
with drug susceptible TB [44–46]. In SHINE, unlike in
these adult trials, smear-negative children with non-
severe paucibacillary disease will use revised doses of
first-line anti-TB drugs. In addition, the trial will also
demonstrate whether the PK parameters and safety pro-
file of the new dosing recommendations for rifampicin,
isoniazid, pyrazinamide and ethambutol across popula-
tions of Indian and African children are adequate. As TB
often occurs alongside HIV infection, SHINE will
provide answers for optimal anti-TB drug dosing in HIV
co-infected children on concomitant ART. The nested
economic and social science substudies enable SHINE to
rapidly translate findings into budget relevant, patient-
oriented, and context-sensitive policy guidance.
TB studies in children have long been neglected owing
to the perception that paediatric TB is not a public
health priority. Paediatric TB trials, in particular, face
challenges because of difficulties in confirming TB bac-
teriological conversion as a study endpoint [8]. While
acknowledging the limitations associated with the estab-
lishment of paediatric TB diagnosis and evaluating end-
points, both clinically diagnosed and bacteriologically
confirmed cases of non-severe TB will be included,
reflecting the pragmatic approaches utilised in routine
clinical settings where children are diagnosed, treated
and monitored predominantly using clinical and radio-
logical parameters. The TB diagnoses and primary end-
points will be adjudicated by an independent ERC,
blinded to the study arms, against the standard paediat-
ric TB research consensus criteria [23, 51, 56]. The trial
will utilise a centralised imaging review by independent
paediatric TB radiology experts to assist with decisions
on the endpoints. Although the main primary analysis
will include all randomised children, it is anticipated that
some children might not have TB, thus contributing to a
non-inferiority outcome. To overcome this, the study
was powered for demonstration of non-inferiority in a
key subpopulation considered to have TB by the ERC.
The trial includes HIV-infected children as current
evidence suggests no association between treatment
duration and outcomes in patients on ART receiving
rifampicin-containing regimens [57]. According to
WHO guidance and existing programmatic approaches,
HIV-infected and uninfected children should be treated
for the same duration [18, 36]. Ethically, the risk profile
of the trial will be similar to existing recommended
approaches in routine clinical practice for TB treatment
in children, regardless of HIV status.
Economic analyses will assess the cost-effectiveness of
reducing treatment from 6 months to 4 months while
the social science analyses will evaluate the palatability
and acceptability of using the recently implemented
paediatric anti-tuberculosis FDCs.
SHINE will confirm whether or not treatment-
shortening of drug susceptible TB in children is effica-
cious and safe. It will also fill existing gaps in knowledge
on dosing of the new anti-TB formulations and com-
monly used HIV drugs in settings with a high burden of
childhood TB. A positive result from this trial (i.e. if
4 months is shown to be non-inferior to 6 months) will
be to simplify treatment, to potentially improve adher-
ence and to reduce treatment costs for a large propor-
tion of children with TB (Additional file 1).
Trial status
The first child was enrolled to SHINE in July 2016 and
recruitment is due to finish by the end of June 2018.
Additional file
Additional file 1: SPIRIT 2013 Checklist: recommended items to address
in a clinical trial protocol and related documents. (DOC 125 kb)
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